ASX: IPD

5 May 2014

ASX ANNOUNCEMENT

L-Dex® featured at key international conference

Brisbane, Australia –**ImpediMed Limited** (ASX: IPD) ("the Company"), is pleased to announce that five of the United States' leading lymphoedema experts presented new data on the use of **ImpediMed's** L-Dex technology. The presentations were delivered at a special symposium, "*Behind the Breakthrough: L-Dex® Data • Outcomes • Survivorship*", during the 15th annual meeting of the American Society of Breast Surgeons (ASBrS) held in Las Vegas on April 30 – May 4, 2014.

The presentations highlighted the significant advances being made in the early detection of lymphoedema, and the role that L-Dex can play in improving patient outcomes. The symposium was attended by over 60 surgeons.

Pat W. Whitworth, MD, FACS started the proceedings with an overview of lymphoedema incidence rates and the use of L-Dex in his practice. Since commencing his surveillance model using L-Dex in 2008, he has observed a diminishing need for Manual Lymphatic Drainage (MLD) in his practice. Dr. Whitworth commented "My therapist complained she was rarely using her (MLD) skills."

Alison L. Laidley, MD, FACS and Beth V. Anglin, MD, FACS presented a retrospective study, in which the incidence of breast cancer related chronic lymphoedema following early intervention was greatly reduced. This data shows improved outcomes compared to historic rates of clinically assessed lymphedema. Early assessment and early intervention improves patient quality of life. "I am very excited about our finds and to have an objective tool that is as easy to use as L-Dex", said Dr. Laidley.

Andrea V. Barrio, MD, FACS presented early data from a randomised control trial at Bryn Mawr Hospital along with interesting case studies. "There is real value in using L-Dex technology, not only for early detection of pre-clinical lymphoedema, which has shown to improve patient outcomes, but also to monitor the effectiveness of treatment" stated Dr. Barrio.

Frank A. Vicini, MD, FACR presented details of the ImpediMed-sponsored, five-year, multi-centre clinical trial to study lymphoedema outcomes. The clinical trial was previously announced on 30 October, 2013.

Richard Carreon
CEO

ENDS

For further information contact:

Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au